ANKARA, Dec. 24 (Reuters) – A COVID-19 vaccine developed by Sinovac Biotech of China is 91.25% effective, and the rate is likely to increase based on late-phase data, Turkish researchers said Thursday as the country second trial. site to produce results for the Chinese candidate.
The researchers, who are part of the government’s science council, said no significant symptoms were detected during the trials of CoronaVac in Turkey, except for one person who had an allergic reaction.
Turkey had agreed to purchase 50 million doses of Sinovac’s CoronaVac by December 11, but the shipment was delayed. Health Minister Fahrettin Koca said the vaccines would arrive in Turkey on Monday, adding that Turkey would vaccinate about 9 million people in the first group, starting with health workers. (Reported by Tuvan Gumrukcu and Ali Kucukgocmen; edited by Alex Richardson)